If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory service entitled Human Immunodeficiency Virus, Decision Resources is offering an exclusive analyst call entitled The New HIV Pipeline: Where Have All the Drugs Gone and Has Virological Failure Doomed Rilpivirine’s Status as a Rising Star? Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. Merck’s recent abandonment of vicriviroc was the latest in a series of disappointing finishes for agents that had once held promise in the emerging therapy pipeline for HIV. Clinical trial results for two of the key remaining players, Tibotec’s rilpivirine and ViiV Healthcare’s S/GSK-1265744, which were presented at the recent XVIII International AIDS Conference 2010 have led to refined expectations for new HIV therapies. This 15-minute analyst call, presented by Decision Resources Analyst Courtney Stanton, Ph.D., will answer the following questions:
Dr. Stanton will conduct a live Q & A session after the presentation. Registration The New HIV Pipeline: Where Have All the Drugs Gone and Has Virological Failure Doomed Rilpivirine’s Status as a Rising Star? August 4, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Courtney Stanton, Ph.D. is a research analyst at Decision Resources, specializing in infectious diseases. She is also a registered patent agent with professional experience in intellectual property law. She most recently served as a technology advisor at Harbor Consulting IP Services where she prepared materials for biotechnology patent applications. Dr. Stanton earned her Ph.D. in Chemistry from the University of California Los Angeles, where she authored several publications in peer-reviewed journals, and was awarded a fellowship to perform primary research at the Lawrence Livermore National Laboratory. She also earned a B.A. in Biochemistry from Smith College.